SEC Form 4 · accession 0001179110-18-008049
HALOZYME THERAPEUTICS, INC. · HALO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dimitrios Chondros
Officer — SVP, Chief Medical Officer
Period of report
Jun 1, 2018
Accepted (ET)
Jun 5, 2018 · 4:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001159036
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 1, 2018 | M | 2,043 | $0.00 | A | 36,119 | D | |
| Common StockF1 | Jun 1, 2018 | F | 712 | $18.59 | D | 35,407 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF2 | $0.00 | Jun 1, 2018 | M | 2,043 | D | — | — | Common Stock | 2,043 | 6,127 | D |
Explanation of responses
- F1The reported disposition of 712 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations.
- F2This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.